2015 Press Releases

»2015 Press Releases
15 12, 2015

Eiger BioPharmaceuticals Announces Notice of Allowance for U.S. Patent Covering Bestatin™ (Ubenimex) for the Treatment of Pulmonary Arterial Hypertension

2017-02-07T18:40:46+00:00

Eiger BioPharmaceuticals Announces Notice of Allowance for U.S. Patent Covering Bestatin™ (Ubenimex) for the Treatment of Pulmonary Arterial Hypertension PALO ALTO, Calif., December 15, 2015 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. today announced the issuance of a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for U.S. patent application number 13/839,321, entitled “Treatment [...]

Eiger BioPharmaceuticals Announces Notice of Allowance for U.S. Patent Covering Bestatin™ (Ubenimex) for the Treatment of Pulmonary Arterial Hypertension2017-02-07T18:40:46+00:00
30 11, 2015

Eiger BioPharmaceuticals Granted Orphan Drug Status for Ubenimex in Pulmonary Arterial Hypertension

2017-02-07T18:42:47+00:00

Eiger BioPharmaceuticals Granted Orphan Drug Status for Ubenimex in Pulmonary Arterial Hypertension PALO ALTO, Calif., November 30, 2015 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. today announced that the US Food and Drug Administration (FDA) has granted Orphan Drug status to ubenimex for the treatment of pulmonary arterial hypertension (PAH). "The FDA Office of Orphan Products Development (OOPD) evaluates scientific and [...]

Eiger BioPharmaceuticals Granted Orphan Drug Status for Ubenimex in Pulmonary Arterial Hypertension2017-02-07T18:42:47+00:00
19 11, 2015

Eiger BioPharmaceuticals and Celladon Corporation Sign Merger Agreement

2017-02-07T18:44:36+00:00

Eiger BioPharmaceuticals and Celladon Corporation Sign Merger Agreement   --Celladon-Eiger proposed merger creates a biopharmaceutical company with diverse portfolio of four novel drug development programs addressing orphan diseases-- --Concurrent financing of $39.5 million from investor syndicate-- --Combined organization expected to be capitalized with greater than $60 million in cash to support company through multiple Phase 2 [...]

Eiger BioPharmaceuticals and Celladon Corporation Sign Merger Agreement2017-02-07T18:44:36+00:00
12 11, 2015

Eiger Announces Acquisition of Exclusive License to Program for Treatment of Post-Bariatric Hypoglycemia from Stanford University

2017-02-07T18:46:01+00:00

Eiger BioPharmaceuticals Announces Acquisition of Exclusive License to Program for Treatment of Post-Bariatric Hypoglycemia from Stanford University - Clinical Proof of Concept Data Already Generated in Patients PALO ALTO, Calif., November 12, 2015 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. today announced that it has acquired an exclusive license to a targeted therapeutic for treating post-bariatric surgical hypoglycemia.  [...]

Eiger Announces Acquisition of Exclusive License to Program for Treatment of Post-Bariatric Hypoglycemia from Stanford University2017-02-07T18:46:01+00:00
11 11, 2015

Eiger Bio Announces Acquisition of Exclusive License to Lymphedema Program from Stanford University

2017-02-07T18:47:42+00:00

Eiger Bio Announces Acquisition of Exclusive License to Lymphedema Program from Stanford University Novel Target Identified as Potential Therapeutic Approach for Lymphedema PALO ALTO, Calif., November 11, 2015 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. today announced that it has acquired an exclusive license to technology for targeting effects of leukotriene B4 (LTB4) to reverse structural tissue changes [...]

Eiger Bio Announces Acquisition of Exclusive License to Lymphedema Program from Stanford University2017-02-07T18:47:42+00:00
10 11, 2015

Eiger Bio Announces Acquisition of Exclusive License to Pulmonary Arterial Hypertension (PAH) Program from Stanford University

2017-02-07T18:49:21+00:00

Eiger Bio Announces Acquisition of Exclusive License to Pulmonary Arterial Hypertension (PAH) Program from Stanford University Novel Target Identified as Potential Therapeutic Approach to PAH PALO ALTO, Calif., November 10, 2015 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. today announced that it has acquired an exclusive license to technology for targeting effects of leukotriene B4 (LTB4) to modulate [...]

Eiger Bio Announces Acquisition of Exclusive License to Pulmonary Arterial Hypertension (PAH) Program from Stanford University2017-02-07T18:49:21+00:00
9 11, 2015

Eiger Bio Announces License Agreement with Nippon Kayaku to Develop Bestatin™ (ubenimex)

2017-02-07T18:51:26+00:00

Eiger BioPharmaceuticals Announces License Agreement with Nippon Kayaku to Develop Bestatin™ (ubenimex) for Inflammatory Diseases Involving LTB4 First Clinical Target – Pulmonary Arterial Hypertension (PAH) PALO ALTO, Calif., November 9, 2015 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. today announced a license agreement with Nippon Kayaku Co., Ltd., Tokyo, Japan, to develop Bestatin™ (ubenimex) for [...]

Eiger Bio Announces License Agreement with Nippon Kayaku to Develop Bestatin™ (ubenimex)2017-02-07T18:51:26+00:00
23 10, 2015

Eiger Bio Appoints Thomas J. Dietz, Ph.D. to the Eiger Board of Directors

2017-02-07T18:52:52+00:00

Eiger Bio Appoints Thomas J. Dietz, Ph.D. to the Eiger Board of Directors PALO ALTO, Calif., October 22, 2015 / PRNewswire / -- Eiger BioPharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of targeted therapies for Orphan Designation diseases, announced today the appointment of Thomas J. Dietz, Ph.D. to its [...]

Eiger Bio Appoints Thomas J. Dietz, Ph.D. to the Eiger Board of Directors2017-02-07T18:52:52+00:00
20 10, 2015

Eiger Bio Appoints Eduardo Martins, MD, DPhil, as Senior VP, Liver and Infectious Diseases Drug Development

2017-02-07T18:54:13+00:00

Eiger Bio Appoints Eduardo Martins, MD, DPhil, as Senior VP, Liver and Infectious Diseases Drug Development PALO ALTO, Calif., October 20, 2015 / PRNewswire / -- Eiger BioPharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of targeted therapies for Orphan Designation diseases, announced today the appointment of Eduardo B. Martins, MD, DPhil, as the [...]

Eiger Bio Appoints Eduardo Martins, MD, DPhil, as Senior VP, Liver and Infectious Diseases Drug Development2017-02-07T18:54:13+00:00
17 08, 2015

Eiger Bio Announces Key Operational Hires to Senior Management Team

2017-02-07T18:55:38+00:00

Eiger Bio Announces Key Operational Hires to Senior Management Team PALO ALTO, Calif., August 17, 2015 /PRNewswire/ — Eiger BioPharmaceuticals, Incorporated, a biopharmaceutical company focused on the development and commercialization of therapies for Orphan Diseases, announced today the appointments of James Welch, as the Company’s Chief Financial Officer and James Shaffer, as the [...]

Eiger Bio Announces Key Operational Hires to Senior Management Team2017-02-07T18:55:38+00:00